Section Arrow
Quote
REGN.NASDAQ
- Regeneron Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/31 22:21 EDT
Regular Hours
Last
 614.78
-6.74 (-1.08%)
Day High 
624.4675 
Prev. Close
621.52 
1-M High
730.59 
Volume 
2.19M 
Bid
613.01
Ask
620
Day Low
609.77 
Open
620.11 
1-M Low
610.6 
Market Cap 
65.16B 
Currency 美元 
P/E 15.01 
%Yield 0.59 
10-SMA 648.62 
20-SMA 680.36 
50-SMA 721.93 
52-W High 821.11 
52-W Low 476.4869 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
40.96/47.74
Enterprise Value
67.87B
Balance Sheet
Book Value Per Share
299.73
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
14.34B
Operating Revenue Per Share
124.93
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1172-0.0468-28.54%-- 
REPLReplimune Group8.69+4.01+85.68%-- 
CDTCDT Equity Inc.1.04+0.0899+9.46%-- 
CMNDClearmind Medicine Inc.3.58+1.13+46.12%-- 
OTLKOutlook Therapeutics0.73-0.01-1.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.